PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
21737767-3	2011	The purpose of the current study was to examine whether, in a controlled study, bupropion would improve the symptoms of RLS, or at least not exacerbate them.	Bupropion	80-89	RLS1	Homo sapiens	120-123	
27994356-1	2016	BACKGROUND: We aimed to compare the efficacy of fixed doses of bupropion and ropinirole and iron alone for the treatment of restless legs syndrome (RLS) and to look for the tolerability of these medications.	Bupropion	63-72	RLS1	Homo sapiens	148-151	
21737767-10	2011	Bupropion was more effective than placebo in the treatment of RLS at 3 weeks; however, this difference was not statistically significant at 6 weeks.	Bupropion	0-9	RLS1	Homo sapiens	62-65	
21737767-11	2011	CONCLUSIONS: The data from our study suggest that bupropion does not exacerbate the symptoms of RLS and may be a reasonable choice if an antidepressant is needed in individuals with RLS.	Bupropion	50-59	RLS1	Homo sapiens	182-185	
21737767-12	2011	Larger studies that include titration of bupropion should be considered to determine if bupropion is appropriate for primary treatment of RLS, particularly considering the lower cost and favorable side effect profile compared with currently recommended first-line dopamine agonists.	Bupropion	88-97	RLS1	Homo sapiens	138-141	
17189751-9	2007	Bupropion could potentially "correct" dopaminergic dysfunction in RLS, and sertraline appears to be the SSRI that provides the least risk of RLS by blocking dopamine reuptake.	Bupropion	0-9	RLS1	Homo sapiens	66-69	
19193596-1	2009	OBJECTIVE: To describe a case of restless legs syndrome (RLS) successfully managed with bupropion.	Bupropion	88-97	RLS1	Homo sapiens	57-60	
19193596-7	2009	Although not widely used for RLS, bupropion XL (Wellbutrin XL) 150 mg daily was initiated, resulting in resolution of RLS within 3 days.	Bupropion	48-61	RLS1	Homo sapiens	118-121	
19193596-11	2009	This case supports findings from other cases suggesting a beneficial response with bupropion for the management of RLS.	Bupropion	83-92	RLS1	Homo sapiens	115-118	
19193596-12	2009	CONCLUSION: Bupropion may be a treatment option for patients who have RLS and are unable to tolerate dopamine agonists.	Bupropion	12-21	RLS1	Homo sapiens	70-73	
16340389-4	2005	The authors report that a low dose of bupropion rapidly and completely ameliorated RLS symptoms in 3 depressed patients within a few days of the initiation of treatment.	Bupropion	38-47	RLS1	Homo sapiens	83-86	
16340389-5	2005	To their knowledge, this is the first report to show that bupropion may be an effective alternative for treating RLS.	Bupropion	58-67	RLS1	Homo sapiens	113-116	
16340389-6	2005	Consequently, bupropion may be useful for the treatment of patients with both depression and RLS.	Bupropion	14-23	RLS1	Homo sapiens	93-96